Dualitas Therapeutics and Roche Launch $1B Bispecific Collaboration
SOUTH SAN FRANCISCO, Calif. — September 17, 2026 Dualitas Therapeutics announced a research collaboration and license agreement with Roche...
Antibody Therapeutics
Advertisement
Harbour BioMed Wins NMPA IND Approval for HBM7004
Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...
Ono Pharma Partners with Mediar to Develop Novel Fibrosis Antibodies
OSAKA, Japan & BOSTON, Mass., August 6, 2026 Ono Pharmaceutical Co., Ltd. announced a drug discovery partnership and option...
Kaigene, Taisho Advance KG006 Autoimmune Therapy Deal
ROCKVILLE, Md. and TOKYO, July 30, 2026 Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co.,...
Harbour BioMed, Sinopharm Form Innovation R&D Consortium
Cambridge, MA, Rotterdam, Netherlands, and Shanghai, China – July 27, 2026 Harbour BioMed has entered into a strategic collaboration...
Advertisements
VERAXA Partners with ATUM for BiTAC-TCE Development
ZURICH, Switzerland, July 2, 2026 VERAXA Biotech AG announced the initiation of cell line development for its lead BiTAC®...
Johnson & Johnson Reveals Promising Phase 3 Results for Bispecific Myeloma Therapy
STOCKHOLM, Sweden, June 13, 2026 Johnson & Johnson has announced groundbreaking results from the pivotal Phase 3 MonumenTAL-3 clinical...
Harbour BioMed Secures Major Antibody Patent Victory Over Amgen
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Advertisement
